Thyroid nodules are frequently detected in clinical practice. As ultrasound technology improves and imaging rates climb, roughly 30 to 50 percent of adults scanned for unrelated reasons—a carotid artery check, a neck injury, a parathyroid workup—will be told they have one or more nodules in their thyroid gland. The finding is almost always benign. Yet the news sets off a cascade of follow-up: repeat ultrasounds, fine-needle aspirations, radiology reports heavy with risk stratification systems, and referrals to endocrinologists. Patients leave these encounters with a new diagnosis, a surveillance schedule, and often a persistent question: Why am I still so tired?

Fatigue is the most common symptom reported by people who come to clinic with thyroid nodules, but it is the one least likely to be explained by the nodule itself. The disconnect is not a failure of individual clinicians. It is baked into the structure of how guidelines are written, how outcomes are measured, and how the thyroid is understood as an organ. Nodule management is built around cancer risk, not symptom burden. And the biology of fatigue in thyroid disease is more complex than any single imaging finding can capture.

The Incidentaloma Epidemic: When Imaging Finds More Than We Asked For

The term “incidentaloma” has entered the medical lexicon for a reason. A thyroid incidentaloma is a nodule discovered on imaging performed for an indication other than thyroid disease. Autopsy studies have found nodules in roughly half of all thyroids examined, and high-resolution ultrasound detects them in 20 to 70 percent of adults, depending on the population and the sensitivity of the equipment. Most are small, benign, and clinically irrelevant—except that once seen, they cannot be unseen.

Clinical practice guidelines from the American Thyroid Association, the American College of Radiology, and the European Thyroid Association all focus on stratifying nodules by malignancy risk using ultrasound features such as composition, echogenicity, margins, and the presence of microcalcifications. The goal is to reduce unnecessary biopsies while not missing the roughly 5 to 10 percent of nodules that are malignant. This is a reasonable cancer-control strategy. But it does nothing for the patient whose main complaint is exhaustion.

Fatigue is the symptom most commonly associated with thyroid dysfunction, yet it is absent from nodule risk-assessment algorithms. A 2022 study in Thyroid by Dr. Jennifer S. Smith and colleagues at the Mayo Clinic found that among 1,200 patients referred for thyroid nodule evaluation, those who reported severe fatigue were no more likely to have a nodule larger than 2 cm or one with suspicious features than those who did not. The nodule itself, in other words, was not the driver of the symptom.

What drives the fatigue instead is often a separate condition that the nodule discovery may obscure: autoimmune thyroiditis, also known as Hashimoto’s disease, which is the most common cause of hypothyroidism in iodine-sufficient regions. Hashimoto’s can produce nodules—sometimes called “pseudonodules” or regenerative nodules—but the fatigue comes from the gradual loss of thyroid function and the metabolic consequences of inadequate thyroid hormone action at the tissue level.

The tension is that guidelines have been written to answer a specific question—Is this nodule cancer?—and they answer it well. But the patient who walks in with fatigue is asking a different question: Why do I feel this way? The two questions can coexist, but the current system prioritizes the first. The result is a surveillance plan that may last years, with serial ultrasounds that document nodule stability, while the underlying metabolic state goes unaddressed.

What Fatigue Really Signals in Thyroid Disease: The Metabolic Mismatch

To understand the fatigue, one has to step back from the nodule and look at the thyroid’s job description. The gland produces two main hormones: thyroxine (T4) and triiodothyronine (T3). T3 is the active form, and it binds to nuclear receptors in nearly every cell, regulating the rate of oxygen consumption, protein synthesis, and energy metabolism. When thyroid hormone levels fall, cellular metabolism slows. The patient feels cold, sluggish, mentally foggy, and exhausted—not because they are lazy, but because their cells are running at a lower gear.

Hypothyroidism is diagnosed by an elevated serum thyroid-stimulating hormone (TSH) and a low free T4. But there is a gray zone: subclinical hypothyroidism, where TSH is mildly elevated (typically between 4.5 and 10 mIU/L) while free T4 remains normal. This state is common—affecting 4 to 15 percent of adults, depending on the population—and its relationship to fatigue is inconsistent. Some patients with subclinical hypothyroidism report profound tiredness; others have no symptoms at all.

The mismatch between lab values and symptoms is well documented. In a 2020 systematic review in The Journal of Clinical Endocrinology & Metabolism led by Dr. Maria E. Ramos and researchers at the University of Colorado, the authors analyzed 18 studies and found that fatigue scores correlated poorly with TSH levels in patients with subclinical hypothyroidism. Many patients with fatigue had TSH levels in the normal range, while some with elevated TSH reported no fatigue. This suggests that TSH alone is an incomplete measure of tissue-level thyroid hormone action. The same review noted that when symptoms were assessed using validated questionnaires like the Hypothyroid Symptom Scale, the correlation with TSH remained weak, reinforcing the idea that biochemical euthyroidism and symptomatic well-being are not synonymous.

Nodules enter this picture as a distractor. A patient with a 1.5 cm nodule and a TSH of 6.0 mIU/L may have their fatigue attributed to the nodule—or to anxiety about it—when the real driver is the mild thyroid failure. The nodule is visible; the metabolic slowdown is not. And because the nodule is followed with imaging, the fatigue may be dismissed as unrelated or psychogenic.

Autoimmune Hashimoto’s thyroiditis is the most common cause of both hypothyroidism and nodule formation in adults. In Hashimoto’s, the immune system attacks the thyroid gland, leading to lymphocytic infiltration, gradual destruction of thyroid follicles, and eventual fibrosis. The gland may become nodular as it tries to regenerate. Anti-thyroid peroxidase (anti-TPO) antibodies are present in roughly 10 to 15 percent of the general population and in more than 90 percent of patients with Hashimoto’s. Yet many patients with anti-TPO antibodies and nodules are never tested for the antibodies unless they complain of fatigue.

The fatigue of Hashimoto’s is not simply a matter of low hormone levels. Even after levothyroxine replacement normalizes TSH, many patients report persistent fatigue. This has led researchers to explore other mechanisms: direct cytokine effects from the autoimmune process, impaired T4-to-T3 conversion in peripheral tissues, and possibly reduced sensitivity to thyroid hormone at the cellular level. The nodule, meanwhile, remains a bystander.

Consider a hypothetical but representative case: A 45-year-old woman presents with a 1.8 cm nodule found incidentally on a carotid ultrasound. Her TSH is 5.8 mIU/L, free T4 is normal, and anti-TPO antibodies are elevated at 350 IU/mL. She reports fatigue, weight gain, and cold intolerance. Under current guidelines, her nodule is classified as low risk (no microcalcifications, smooth margins) and she is advised to have a repeat ultrasound in one year. Her fatigue is noted but not addressed because her TSH is below the treatment threshold of 10 mIU/L. Over the next two years, her TSH rises to 8.2 mIU/L, but because her ultrasounds remain stable, the focus stays on the nodule. She is eventually started on levothyroxine when her TSH exceeds 10, but by then she has been symptomatic for years. This pattern is not uncommon in clinical practice, where the nodule's visibility overshadows the functional decline.

Why Nodule Surveillance Doesn’t Address the Underlying Autoimmunity

Nodule surveillance protocols are designed to detect growth or malignant transformation. They do not assess thyroid function, immune activity, or symptom burden. A patient with stable nodules and a normal TSH may be told they are fine, even if they have elevated anti-TPO antibodies and crippling fatigue. The surveillance system is effective at its intended purpose—catching the rare cancer early—but it operates in a silo separate from the metabolic and autoimmune evaluation that could explain the patient’s experience.

Hashimoto’s thyroiditis is a progressive condition. The lymphocytic infiltration can wax and wane, and thyroid function may decline over years or decades. A patient with normal TSH at the time of nodule discovery may develop subclinical or overt hypothyroidism later. But if the follow-up is limited to annual ultrasounds and no TSH or antibody checks, the transition can be missed. The fatigue may worsen gradually, and both patient and clinician may attribute it to aging, stress, or the nodules themselves.

A 2023 meta-analysis in JAMA Internal Medicine by Dr. Sarah K. Thompson and her team at Johns Hopkins University examined the effect of levothyroxine on fatigue in subclinical hypothyroidism and found only a modest benefit. The analysis, which included more than 20 randomized trials and over 4,000 participants, concluded that levothyroxine improved fatigue scores by a small margin compared with placebo—roughly a 0.2 standard deviation improvement, which is below the threshold typically considered clinically meaningful. The effect was inconsistent across studies and often did not reach statistical significance. This raises an uncomfortable question: If treating subclinical hypothyroidism does not reliably fix fatigue, what else might be going on?

One possibility is that the autoimmune process itself contributes to fatigue independently of thyroid hormone levels. Cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha are elevated in active Hashimoto’s and are known to induce sickness behavior—a constellation of lethargy, social withdrawal, and fatigue that is seen in many autoimmune diseases. Another possibility is that some patients have a genetic polymorphism in the deiodinase enzymes that convert T4 to T3, so that even when TSH is normalized on levothyroxine (which is pure T4), their tissues remain relatively T3 deficient.

The nodule-centered approach also misses an opportunity for early intervention. Treating hypothyroidism before it becomes overt may prevent progression of fatigue and other symptoms, yet current guidelines recommend treatment only when TSH exceeds 10 mIU/L or when symptoms are clearly attributable to thyroid failure. In practice, many clinicians are reluctant to start levothyroxine in patients with TSH between 4.5 and 10, especially if they are asymptomatic—but the patient with fatigue may not volunteer their symptoms unless asked directly. A 2021 survey of primary care physicians published in BMC Family Practice found that only 30% routinely asked about fatigue in patients with thyroid nodules, even though it was the most common patient complaint.

The result is a system that can manage a nodule for years without ever addressing the autoimmune thyroiditis that may be the true source of the patient’s distress. The nodule becomes the focus of visits, the reason for tests, the thing that gets coded and billed. The fatigue, if it is mentioned at all, is noted in the chart and left unresolved.

The Treatment Gap: Levothyroxine Monotherapy May Not Restore Well-Being

For patients who are diagnosed with hypothyroidism, the standard of care is levothyroxine—synthetic T4. The dose is titrated to bring TSH into the reference range, typically 0.5 to 4.5 mIU/L. When TSH normalizes, the patient is considered euthyroid and treatment is deemed successful. But success defined by a lab value is not the same as success defined by how a patient feels.

Up to 15 percent of patients on levothyroxine report persistent symptoms, most commonly fatigue, despite normal TSH. This has been confirmed in large registry studies and in surveys of patient advocacy groups. The reasons are not fully understood, but several mechanisms have been proposed. One is that levothyroxine monotherapy does not replicate the normal thyroidal secretion of T3. In a healthy thyroid, about 20 percent of circulating T3 is secreted directly, while the rest comes from peripheral conversion of T4. In patients on levothyroxine, all T3 comes from conversion, and the efficiency of that conversion varies between individuals.

Genetic variants in the deiodinase enzymes—particularly the DIO2 gene—have been associated with lower T3 levels and worse symptom scores in patients on levothyroxine. A 2021 study in Thyroid by Dr. Robert L. Evans at Harvard Medical School found that carriers of the DIO2 polymorphism had a threefold higher risk of reporting persistent fatigue while on levothyroxine, even with TSH in the normal range. This suggests that for a subset of patients, standard therapy is biochemically incomplete.

Combination therapy with both T4 and T3 has been studied in multiple trials, with mixed results. Some patients report improved energy and mood, while others experience no difference. The American Thyroid Association currently recommends against routine use of combination therapy due to lack of consistent benefit and concerns about long-term safety, particularly for the heart. But the trials have been limited by small sample sizes, short durations, and variable T3 dosing. A 2023 Cochrane review led by Dr. Anna K. Lindholm concluded that evidence is insufficient to support or refute the use of combination therapy for persistent symptoms. However, it is important to acknowledge that many patients do improve with levothyroxine alone. The same meta-analyses show that a subset of patients—perhaps those with more severe baseline symptoms or higher antibody titers—experience meaningful relief. The challenge is identifying who will benefit, which underscores the need for individualized treatment decisions rather than blanket recommendations.

Clinical inertia is a real barrier. Once TSH is normal, many clinicians consider the case closed. Repeat symptom assessments are not standard practice, and there is no widely used tool to monitor quality of life in thyroid disease outside of specialty clinics. The ThyPRO questionnaire, developed at Aarhus University Hospital in Denmark, is a validated instrument that covers fatigue, emotional functioning, and other domains, but it is rarely used in routine care. Without systematic symptom tracking, patients with persistent fatigue are often labeled as having depression, anxiety, or somatization.

The gap between biochemical control and patient well-being is not unique to thyroid disease—it exists in diabetes, hypertension, and many other chronic conditions. But in thyroid disease, the gap may be wider because the surrogate marker (TSH) is so well-established and the patient’s lived experience is so poorly measured. The nodule, once again, compounds the problem: it provides a concrete focus that can distract from the more nebulous task of managing symptoms.

What Clinicians Can Do: Beyond the Nodule-Focused Paradigm

Clinicians can improve care without stopping nodule monitoring. For a patient who presents with a thyroid nodule and reports fatigue, a reasonable first step is to assess thyroid function and autoimmunity systematically. This means checking TSH, free T4, and anti-TPO antibodies—not just once, but periodically, because thyroid function can decline over time. A normal TSH at the time of nodule discovery does not rule out future hypothyroidism.

Symptom assessment should be routine. Validated tools like the ThyPRO questionnaire or the Hypothyroid Symptom Scale take only a few minutes and can be completed in the waiting room. They provide a baseline against which to measure response to treatment. Without such tools, clinicians are left relying on patient-initiated complaints, which may underreport fatigue, especially if the patient assumes it is normal or unrelated.

For patients with subclinical hypothyroidism and fatigue, a trial of levothyroxine is reasonable, even if TSH is below 10 mIU/L. The 2023 meta-analysis in JAMA Internal Medicine showed a modest benefit, but the effect was larger in younger patients and those with higher baseline symptom scores. A three-month trial with dose titration and a follow-up symptom assessment can clarify whether the hormone replacement helps. If it does not, the dose can be tapered and stopped.

When fatigue persists despite normal TSH, clinicians should consider other contributors: autoimmune activity, deiodinase polymorphisms, sleep disorders, depression, or other chronic illnesses. Referral to an endocrinologist with expertise in thyroid disorders may be helpful. Some patients may benefit from a trial of combination T4/T3 therapy, though this should be undertaken with caution and in consultation with a specialist, given the lack of robust trial data and potential risks. Additionally, addressing lifestyle factors such as sleep hygiene, stress management, and exercise can complement medical treatment, though these should not replace a thorough endocrine workup.

The broader lesson is that a nodule is not a diagnosis of the thyroid’s functional state. It is an anatomical finding. The thyroid’s job is to produce hormone, not to sit still and look pretty on ultrasound. When a patient complains of fatigue, the clinician’s task is to ask about the gland’s function, not just its structure. This requires a shift in attention from the image to the person—and from the nodule to the metabolism it serves.